New Delhi, Sep 20 (IANS) A team of researchers has identified critical biomarkers that can predict disability worsening in people with multiple sclerosis (MS) — a chronic autoimmune disease that affects the central nervous system (CNS).
The findings can potentially transform treatment strategies for millions of people suffering from MS worldwide, and will also pave the way for more personalised and effective treatment plans.
The team from Hospital Universitario Ramon y Cajal in Spain conducted an observational study on 725 MS patients, across 13 hospitals in Spain and Italy.
They found that high levels of serum neurofilament light chain (sNfL) — a protein indicating nerve cell damage — at the onset of MS could predict both relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA).
In addition, levels of serum glial fibrillary acidic protein (sGFAP) — a protein derived from astrocytes that enter the bloodstream when the central nervous system (CNS) is injured or inflamed — correlate with PIRA in patients with low levels of sNfL. High sGFAP levels indicated more localised inflammation driven by microglia in the CNS and are also known to be associated with progression.
Dr. Enric Monreal and his team at the Hospital analysed blood samples from the 725 MS patients collected within 12 months of disease onset.
Their findings reveal that higher sNfL levels are indicative of acute inflammation within the CNS in MS. These were associated with a 45 per cent increased risk of RAW and a 43 per cent increased risk of PIRA.
While people with high sNfL levels often did not respond well to standard disease-modifying treatments (DMTs), they showed significant benefits from high-efficacy DMTs such as Natalizumab, Alemtuzumab, Ocrelizumab, Rituximab, and Ofatumumab.
Monreal, a researcher in MS, suggested measuring both sNfL and sGFAP levels at disease onset, which will help tailor treatment strategies for MS patients more effectively.
The researcher explained that this will mean people with low levels of both biomarkers, who show good prognosis, can be treated via injectable or oral DMTs.
Current DMTs primarily target the peripheral adaptive immune system without affecting CNS immunity. Thus, finding people “with higher levels of peripheral inflammation is crucial for preventing disability and improving patient outcomes,” Monreal said
The results were presented at the 40th European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2024) Congress in Copenhagen, Denmark.
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
